|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 14:51
|
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 (GlobeNewswire EN)
|
|
|
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET....
|
|
|
|
|
|
|
|
|
24.07.26 - 21:24
|
XFRA: 41O: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
OUTLOOK THERAP. DL-,01 41O US69012T3059
AB/FROM ONWARDS 24.07.2026 21:05 CET...
|
|
|
|
|
|
|
24.07.26 - 20:01
|
XFRA: 41O: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
OUTLOOK THERAP. DL-,01 41O US69012T3059 BAW/UFN...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
